Atypicality of atypical antipsychotics

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 7, Issue 6, 2006, Pages 268-274

  Farah, Andrew ^a,b  

^a High Point Regional Health System   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN UPTAKE INHIBITOR; ZIPRASIDONE;

AGRANULOCYTOSIS; AKATHISIA; ANTICHOLINERGIC EFFECT; ANXIETY; BIPOLAR I DISORDER; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; CONSTIPATION; DIABETES MELLITUS; DIZZINESS; DOSE RESPONSE; DRUG INFORMATION; DRUG INHIBITION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; GRANULOCYTOPENIA; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERPROLACTINEMIA; INSOMNIA; MEDLINE; METABOLIC DISORDER; MYOCARDITIS; NAUSEA; ORTHOSTATIC HYPOTENSION; PANCREATITIS; PSYCHOSIS; QT PROLONGATION; REVIEW; SCHIZOPHRENIA; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SYNCOPE; UNITED STATES; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT GAIN;

EID: 33745742468     PISSN: 15235998     EISSN: None     Source Type: Journal    
DOI: 10.4088/pcc.v07n0602     Document Type: Review

References (67)

1. Kane JM. Extrapyramidal side effects are unacceptable. Eur Neuropsychopharmacol 2001;11(suppl 4):S397-S403
2. Markowitz JS, Brown CS, Moore TR. Atypical antipsychotics, pt 1: pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother 1999;33:73-85
3. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002;47:27-38
4. Goldstein JM. The new generation of antipsychotic drugs: how atypical are they? Int J Neuropsychopharmacol 2000;3:339-349
5. Beng-Choon H, Black D, Andreasen NC. Schizophrenia and other psychotic disorders. In: Hales R, Yudofsky S, eds. Textbook of Clinical Psychiatry, Fourth Edition. Washington, DC: American Psychiatric Publishing, Inc; 2003:379-438
6. Reynolds GP. What is an atypical antipsychotic? J Psychopharmacol 1997;11:195-199
7. Compton MT, Miller AH. Antipsychotic-induced hyperprolactinemia and sexual dysfunction. Psychopharmacol Bull 2002;36:143-164
8. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999;156:286-293
9. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000;157:514-520
10. Abilify (aripiprazole). Full Prescribing Information. Princeton, NJ: Bristol-Myers Squibb Company; 2005
11. Geodon (ziprasidone). Full Prescribing Information. New York, NY: Pfizer Inc; 2005
12. Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14:87-97
13. Goldstein J. Preclinical profile of Seroquel (quetiapine): an atypical antipsychotic with clozapine-like pharmacology. In: Holliday SG, Ancill RJ, MacEwen GW, eds. Schizophrenia: Breaking Down the Barriers. Hoboken, NJ: John Wiley and Sons Ltd; 1996:177-208
14. Tandon R. Safety and tolerability: how do newer generation "atypical" antipsychotics compare? Psychiatr Q 2002;73:297-311
15. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004;161:414-425
16. Clozaril (clozapine). Full Prescribing Information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2003
17. Risperdal (risperidone). Full Prescribing Information. Titusville, NJ: Janssen Pharmaceutica; 2005
18. Seroquel (quetiapine fumarate). Full Prescribing Information. Wilmington, Del: AstraZeneca Pharmaceuticals LP; 2004
19. Zyprexa (olanzapine). Full Prescribing Information. Indianapolis, Ind: Eli Lilly and Company; 2005
20. Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003;64:134-143
21. Iqbal MM, Rahman A, Husain Z, et al. Clozapine: a clinical review of adverse effects and management. Ann Clin Psychiatry 2003;15:33-48
22. Chen RY, Chen E, Ho WY. A five-year longitudinal study of the regional cerebral metabolic changes of a schizophrenic patient from the first episode using Tc-99m HMPAO SPECT. Eur Arch Psychiatry Clin Neurosci 2000;250:69-72
23. Potkin SG, Alva G, Fleming K, et al. A PET study of the pathophysiology of negative symptoms in schizophrenia. Am J Psychiatry 2002;159:227-237
24. Nordstrom AL, Farde L, Nyberg S, et al. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 1995;152:1444-1449
25. Kapur S, Seeman P. Does fast dissociation from the dopamine D(2) receptor explain the action of atypical antipsychotics? a new hypothesis. Am J Psychiatry 2001;158:360-369
26. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? a review of the evidence. Neuropsychopharmacology 1998;18:63-101
27. Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993;329:162-167
28. Gaszner P, Makkos Z, Kosza P. Agranulocytosis during clozapine therapy. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:603-607
29. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-1696
30. Hagg S, Spigset O, Bate A, et al. Myocarditis related to clozapine treatment. J Clin Psychopharmacol 2001;21:382-388
31. Coulter DM, Bate A, Meyboom RH, et al. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. BMJ 2001;322:1207-1209
32. Rosebush PI, Mazurek MF. Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology 1999;52:782-785
33. Bassitt DP, de Souza Lobo Garcia L. Risperidone-induced tardive dyskinesia. Pharmacopsychiatry 2000;33:155-156
34. Ipekci S, Birsoz S. Tardive dyskinesia caused by the atypical antipsychotic risperidone and cured by the use of another drug of the same class, olanzapine [letter]. Eur Psychiatry 2001;16:259-260
35. Lykouras L, Yannakis R, Hatzimanolis J, et al. Two cases of risperidone-induced tardive dyskinesia and a review of the literature. Eur Psychiatry 1999;14:245-247
36. Magnuson TM, Roccaforte WH, Wengel SP, et al. Medication-induced dystonias in nine patients with dementia. J Neuropsychiatry Clin Neurosci 2000;12:219-225
37. Narendran R, Young CM, Pato MT. Possible risperidone-induced tardive dystonia [letter]. Ann Pharmacother 2000;34:1487-1488
38. Nelson MW, Reynolds RR, Kelly DL, et al. Adjunctive quetiapine decreases symptoms of tardive dyskinesia in a patient taking risperidone. Clin Neuropharmacol 2003;26:297-298
39. Spivak M, Smart M. Tardive dyskinesia from low-dose risperidone [letter]. Can J Psychiatry 2000;45:202
40. Suzuki E, Obata M, Yoshida Y, et al. Tardive dyskinesia with risperidone and anticholinergics [letter]. Am J Psychiatry 2002;159:1948
41. Halbreich U, Kinon BJ, Gilmore JA, et al. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 2003;28(suppl 1):53-67
42. Kinon BJ, Gilmore JA, Liu H, et al. Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology 2003;28(suppl 2):69-82
43. Kapur S, Remington G, Zipursky RB, et al. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci 1995;57:PL103-PL107
44. Glazer WM. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry 2000;61(suppl 3):16-21
45. Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996;124:57-73
46. Kapur S, Zipursky RB, Remington G, et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 1998;155:921-928
47. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001;62(suppl 7):22-31
48. Green AI, Salomon MS, Brenner MJ, et al. Treatment of schizophrenia and comorbid substance use disorder. Curr Drug Target CNS Neurol Disord 2002;1:129-139
49. Arvanitis LA, Miller BG, for the Seroquel Trial 13 Study Group. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-246
50. 2 receptor occupancy. Arch Gen Psychiatry 2000;57:553-559
51. Goldstein J, Zhong K. Tolerance to somnolence with quetiapine ('Seroquel'): preclinical mechanisms and clinical evidence. Presented at the XXIV Collegium Internationale Neuro-Psychopharmacologicum; June 2004; Paris, France
52. Brecher M, Rak IW, Melvin K, et al. The long-term effect of quetiapine ('Seroquel') monotherapy on weight in patients with schizophrenia. Int J Psychiatry Clin Pract 2000;4:287-291
53. Keck P Jr, Buffenstein A, Ferguson J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl) 1998;140:173-184
54. Daniel DG, Zimbroff DL, Potkin SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999;20:491-505
55. Miceli JJ, Wilner KD, Hansen RA, et al. Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers. Br J Clin Pharmacol 2000;49(suppl 1):5S-13S
56. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002;16:23-45
57. Mamo D, Kapur S, Shammi CM, et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 2004;161:818-825
58. Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004;24:62-69
59. Arato M, O'Connor R, Meltzer HY. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol 2002;17:207-215
60. Keck PE Jr, McElroy SL. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. Expert Opin Investig Drugs 2003;12:655-662
61. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, pt 1: "Goldilocks" actions at dopamine receptors [BRAINSTORMS]. J Clin Psychiatry 2001;62:841-842
62. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681-690
63. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63:763-771
64. Lindsey RL, Kaplan D, Koliatsos V, et al. Aripiprazole and extrapyramidal symptoms [letter]. J Am Acad Child Adolesc Psychiatry 2003;42:1268-1269
65. Peralta K, Narayanaswamy S, Cohen H, et al. Aripiprazole-induced extrapyramidal symptoms: a case report. Presented at the 7th annual meeting of the College of Psychiatric and Neurologic Pharmacists; April 22-25, 2004; Chicago, Ill
66. Yokoi F, Grunder G, Biziere K, et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 2002;27:248-259
67. Sajatovic M. Treatment for mood and anxiety disorders: quetiapine and aripiprazole. Curr Psychiatry Rep 2003;5:320-326